• Aucun résultat trouvé

Jazmp lf''IH

N/A
N/A
Protected

Academic year: 2022

Partager "Jazmp lf''IH"

Copied!
3
0
0

Texte intégral

(1)

Jazmp

lf''IH q l•u 1nl•t 11 ('! t ,udut I u1l \1, ,,,, •I fl• •I• • \ ol Uu H't l'uhht •II •lu\u tll1 11111~ A,, I 11114 I Jl, *•I '"''"

',,,1·1,

Ull'

I • 1111, (uJ/1 ''J'h' 'J''•~

I

I,,,(,

(•1)/1 '1««1 •,It)

Agency for medicinal products and medical devices of the Republic of Slovenia

CERTIFICATE NUMBER: 450-29/2013-2

I 2

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER .

Part 1

Issued following an inspection in accordance with : Art. 111 (5) of Directive 200 l/83/EC as amended

The competent authority of Slovenia confirms the following:

The manufacturer: Jadran Galenski Laboratorij d. d. - Svilno Site address: Svilno 20, Rijeka, 51000, Croatia

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. Ill ( 4) of Directive 200 l/83/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2013-06-18, it is consiJcrcJ that it (.ulllplics with:

• The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC 1 This ce11ificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk

management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

1 The authorisation referred to in paragraph 40(1) of Directive 2001/83/EC and 44(1) of Directive 2001182/EC, as amended, shall also be required

for imports coming from third countries into a Member State.

2 Guidance on the interpretation of this template can be found in the Help menu ofEudraGMDP database

3 The Competent Authority is responsible for awropriate linking of the authorisation with the manufacturer's appltcalion (Art. 42{3) of Dtreclll'e 2001/83/EC and Art. 46(3) of Directive 2001182/EC as amended).

Online EudraGMDP, Ref key: 21961 Issuance Date: 2013·12-23 Signatory: Mr M. T. Eisel! Page 1 of 3

(2)

Part 2

Human Medicinal Products

1 MANUFACTURING OPERATIONS 1.1 Sterile products

1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.4 Small volume liquids

1.2 Non-sterile products

1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.11 Semi-solids

1.2.1.13 Tablets

l.2.l.l7 Other: Granules, Oral Powders(en)

l.S Packaging

1.5.1 Primary Packing 1.5.1.11 Semi-solids 1.5.1.13 Tablets

I .5.1. 17 Other non-sterile medicinal rroducts: (ir<mulcs, Oral Powders( en) 1.5.2 Secondary packing

1.6 Quality control testing 1.6.3 Chem icai/Physical

Any n.·striclions related to the scope ofthis certificate :

A.\'t'f'licaf~l' prepared sterile products that are manufactured by the company JGL d. d. are ophthalmic drop.r mrtl nasal solutions.

Clarifying remarks (for public users)

Aseptically prepared sterile products that are manufactured by the company JGL d. d. are ophthalmic drops and nasal solutions.

Online EudraGMDP, Ref key: 21961 Issuance Date: 2013-12-23 Signatory: Mr M. T. Eisel! Page 2 of 3

(3)

2013-12-23

Online EudraGMDP, Ref key: 21961

Name and signature of the authorised person of the Competent Authority of Slovenia

i J ( (

J

Mr Miklrtlll Tadej Bi.l't!ll

AgeltCJI for medit'illttl prutlucts tmrl medical de11ices of lite Republic ofS!ollt:ll/(1

Tel: +3116 112flfiiJ .HH Fax: +386 82(100 630

Issuance Date: 2013·12·23 Signatory: Mr M. T. Eisel! Page 3 of 3

Références

Documents relatifs

Model performance was measured using the relative absolute error (RAE) between observed and predicted rates of emerging alien species. Size of bubbles and colours indicate the

The antiferromagnetic critical point of the Potts model on the square lattice was identified by Baxter [1] as a staggered integrable six-vertex model.. In this work, we investigate

[r]

Afin d’agrandir son offre en Suisse romande et toucher les clients romands, la fondation, disposant de peu de moyens financiers, pourrait être soutenue par les sections romandes de

through which an enterprise can create more long term value and achieve a higher long term competitive advantage, while encountering fewer risks [2], [5]–[7]. However, sus-

Moore and Grove responded to mounting evidence that Intel was behind Japanese producers and some American corporations in microchip fabrication by charging Flath and Kauffman to

L-lactic acid production by Aspergillus brasiliensis overexpressing the heterologous ldha gene from Rhizopus oryzae... To make lactic acid production cost-effective, the

The objective of this arti- cle is related to the potential improvement of computer simulation as applied to the control of manufacturing system by introducing a two-level